| Description |
1 online resource |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Series |
New developments in medical research |
|
New developments in medical research.
|
| Bibliography |
Includes bibliographical references and index. |
| Note |
Print version record. |
| Contents |
Chapter I: Mechanisms of Vascular Remodeling in Pulmonary Arterial Hypertension; Abstract; Introduction; Classification; Symptoms and Diagnosis; Biomarkers; Pathogenesis of PAH; i) Role of Endothelial Cells and Their Cross Talk with Different Cell Types in Vasculature; Endothelial Response to Injury; Endothelial Dysfunction and Vasoconstriction/Vasodilatation. |
|
Endothelial Dysfunction and Impaired AngiogenesisEndothelial Dysfunction and Plexiform Lesions; ii) Role of Inflammation and Autoimmunity; Inflammatory Cells; Cytokines and Chemokines; Molecular Mechanisms Contributing to PAH-PASMC and PAEC Proliferation and Resistance to Apoptosis; The Src/STAT3 Integrative Hub; Metabolic Switch: The Warburg Effect; Epigenetic Mechanisms of PH; Role for miRNAs; DNA Methylation; Modification of Histone Proteins; Potential Implication of Long Noncoding RNA; Vascular Stiffening in PAH: A Cause; or Consequence?; Treatment. |
|
Basic Measures and Conventional TherapiesApproved PAH Therapies; 1) Prostacyclin Pathway; 2) Endothelin Pathway; 3) Nitric Oxide-cGMP Pathway; New Drugs in Early Phase of Development; i) Newer Agents Targeting Established Vasodilatory Pathways; ii) Tyrosine Kinase Inhibition; iii) Serotonin System; iv) Vasoactive Intestinal Peptide; v) RhoA/Rho-Kinase Signaling Pathway; vi) Statins; vii) Apelin; viii) Anti-inflammatory therapies; ix) Restoration of BMPR-II Signaling Axis; Procedures/Nonmedical Therapies; Expected Novel Drugs in Future/ Therapies under Investigation; Gap in Knowledge. |
|
Iv) Neprilysin Knockout ModelOverexpression Models; i) Interleukin-6 Overexpression Model; ii) S100A4/Mts-1 Overexpression Model; Methods to Study PAH; In-vitro Methods; I. Isolation and Culture of Primary Cells; i) Human pulmonary artery endothelial cells from transplant donors; ii) Isolation of pulmonary artery smooth muscle cells; Method; Histological and Morphological Analysis; 1. Hematoxylin and Eosin (H & E) Staining; H & E Staining of Frozen Sections of Pulmonary Artery; Method; H & E Staining for Parrafin Sections of Pulmonary Artery; Method; 2. Masson's Trichrome Staining; Procedure. |
| Summary |
Pulmonary arterial hypertension (PAH) is a progressive, fatal syndrome characterized by increased vascular resistance that leads to right-ventricular hypertrophy and heart failure, eventually leading to death. The chapters of this book describe the molecular mechanisms and cellular events regulating vascular remodeling in PAH; the various animal models and drugs currently being used in various laboratories to study mechanisms leading to pulmonary arterial hypertension; and nifedipine, its pharmacology and it's role in the management of pulmonary hypertension and some of the drawbacks concernin. |
| Subject |
Pulmonary hypertension.
|
|
Pulmonary hypertension -- Chemotherapy.
|
|
Nifedipine -- Therapeutic use.
|
|
Hypertension, Pulmonary |
|
Hypertension pulmonaire.
|
|
Hypertension pulmonaire -- Chimiothérapie.
|
|
Nifédipine -- Emploi en thérapeutique.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Nifedipine -- Therapeutic use
|
|
Pulmonary hypertension
|
| Added Author |
Estrada, Victoria (Editor), editor.
|
| Other Form: |
Print version: Pulmonary arterial hypertension and nifedipine. New York : Nova Biomedical, [2015] 9781634825948 (DLC) 2015936751 |
| ISBN |
9781634826358 (ebook) |
|
1634826353 |
|
1634825942 (hardback) |
|
9781634825948 (hardback) |
|
